![Ann A. Jakubowski, MD, PhD -- Clinical Director, Adult Bone Marrow Transplantation Outpatient Unit](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/node/299/image/jakubowski-ann.jpg?h=10d202d3)
Ann A. Jakubowski, MD, PhD
Bone Marrow Transplant Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Acute and Chronic Leukemia
- Myelodysplastic Syndrome
- Adult Stem Cell Transplantation
Request an Appointment
About Me
- Clinical Director, Adult Bone Marrow Transplantation Outpatient Unit
As a board-certified hematologist-oncologist I have a clinical focus on patients with hematologic diseases, specifically leukemia and myelodysplastic syndrome, and on those who may benefit from any form of stem cell transplantation.
Read more
Patients who undergo transplant usually spend most of their time after transplantation in the outpatient department, so my role as Clinical Director of Memorial Sloan Kettering’s Adult Bone Marrow Transplant Outpatient Unit affords me the opportunity to improve the experience of all of our transplant patients.
Over the past several years my research has involved new approaches to transplantation that reduce transplant-related complications and enhance patients’ immune reconstitution after transplant. These approaches are making transplantation an option for new and expanding populations of patients. This research has also been integral to our developing an adult Survivorship Program for stem cell transplant patients, and has instigated the development of Memorial Sloan Kettering’s 65+ Program for older adults.
In collaboration with colleagues throughout the Center, physicians of the 65+ Program created an assessment tool for older adult patients which is now used by cancer centers throughout the country to evaluate patients prior to treatment. This tool is being incorporated into the screening of older adult patients prior to transplant to assist the physicians in selecting the type of transplant best suited to each patient.
In our Survivorship Clinic, where patients who have undergone transplant receive follow-up care, we have established a program to monitor post-transplant complications in patients of all ages. By reviewing characteristics and outcomes of patients who have already undergone transplant with subspecialists in all of the major medical areas, we identify complications; adapt our screening, treatment, and monitoring programs; and conduct research to improve these outcomes. The results of this monitoring program are being used to help design studies of new transplant methods and to alter transplants to reduce the time that a patient’s immune system is suppressed afterward.
On the national level, my membership on an expert committee for tissue, gene, and cell therapy of the United States Pharmacopeia (USP) — a non-governmental, official public standards-setting authority for healthcare products — has given me the opportunity to participate in the process of standardizing treatment modalities that are at the forefront of medical care and transplantation.
A bone marrow transplant specialist is a doctor with special training in bone marrow transplants.
My Specialties
- Acute and Chronic Leukemia
- Myelodysplastic Syndrome
- Adult Stem Cell Transplantation
Education
- MD, University of Connecticut School of Medicine
- PhD, Wesleyan University
Residencies
- Mount Sinai Medical Center (New York)
Awards and Honors
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
Fellowships
- Montefiore and Albert Einstein Medical Centers
- Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Hematology
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
![Women talking](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/paragraph/131881/cta_image/app-220128-006_rt_1200x800.jpeg?h=10d202d3)
New Patients
Current Patients
Contact and Location
Dr. Jakubowski sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Jakubowski
- A Phase 2 Study of Isatuximab to Treat Low Blood Cell Counts in People With Blood Cancer Who Had a Stem Cell Transplant from a Donor
![Smiling doctors in the lab](/themes/mskcc/images/clinicaltrials_small.png)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Jakubowski’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Ann A. Jakubowski discloses the following relationships and financial interests:
-
Novartis
Equity
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].